Bank of America’s NewAmsterdam Pharma NAMS Stock Holding History

Bank of America’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.9M	Sell	735,483 -111,606	-13%	-$3.68M	﹤0.01%	2297
2026 Q1	$27.1M	Buy	847,089 +387,698	+84%	+$12.6M	﹤0.01%	2132
2025 Q4	$16.1M	Sell	459,391 -12,709	-3%	-$463K	﹤0.01%	2475
2025 Q3	$13.4M	Sell	472,100 -11,904	-2%	-$285K	﹤0.01%	3000
2025 Q2	$8.77M	Sell	484,004 -175,304	-27%	-$3.2M	﹤0.01%	3354
2025 Q1	$13.5M	Buy	659,308 +615,779	+1,415%	+$13.7M	﹤0.01%	2844
2024 Q4	$1.12M	Buy	43,529 +40,819	+1,506%	+$867K	﹤0.01%	4938
2024 Q3	$45K	Sell	2,710 -427	-14%	-$7.39K	﹤0.01%	6575
2024 Q2	$60.3K	Buy	3,137 +1,137	+57%	+$22.8K	﹤0.01%	6455
2024 Q1	$47.3K	Buy	+2,000	New	+$40.6K	﹤0.01%	6532

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Bank of America's NAMS Position: Q2 2026 in Review

Bank of America reduced its NewAmsterdam Pharma (NAMS) stake by 13% in Q2 2026, selling an estimated $3.68M and leaving 735,483 shares worth $24.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2297.

Bank of America first reported a position in NAMS in Q1 2024 and has held it in 10 quarters since. The position peaked at $27.1M in Q1 2026. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Bank of America held 735,483 shares of NewAmsterdam Pharma worth $24.9M as of Q2 2026.
Bank of America sold 111,606 NewAmsterdam Pharma shares in Q2 2026, an estimated $3.68M.
NewAmsterdam Pharma made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2297 holding.
Bank of America first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 10 quarters since.
Bank of America's NewAmsterdam Pharma position peaked at $27.1M in Q1 2026.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.